CBPO [China Biologic Products] SC 13D:
[]
SNP [CHINA PETROLEUM & CHEMICAL] 6-K: (Original Filing)
[This Form 6-K consists of: 1. 2. Announcement 1 (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 00386) Resignation of Director The board of directors (the " Board ") of China Petroleum & Chemical Corporation (" Sinopec Corp. " or the]
SNP [CHINA PETROLEUM & CHEMICAL] 6-K: This Form 6-K consists of: 1. 2. Announcement
[This Form 6-K consists of: 1. 2. Announcement 1 (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 00386) Resignation of Director The board of directors (the " Board ") of China Petroleum & Chemical Corporation (" Sinopec Corp. " or the]
CCCL [China Ceramics] F-3: (Original Filing)
[] [Harney Westwood & Riegels LP Craigmuir Chambers PO Box 71 Road Town Tortola VG1110 British Virgin Islands Tel: +1 284 494 2233 Fax: +1 284 494 3547 23 September 2020 BY EMAIL greg.boyd@harneys.com +1 284 852 4317 GAB/043011.0030 China Ceramics Co., Ltd Junbing Industrial Zone Address Anhai Jinjia]
CCCL [China Ceramics] F-3:
[] [Harney Westwood & Riegels LP Craigmuir Chambers PO Box 71 Road Town Tortola VG1110 British Virgin Islands Tel: +1 284 494 2233 Fax: +1 284 494 3547 23 September 2020 BY EMAIL greg.boyd@harneys.com +1 284 852 4317 GAB/043011.0030 China Ceramics Co., Ltd Junbing Industrial Zone Address Anhai Jinjia]
RENN [Renren] SC 13G/A: (Original Filing)
[SCHEDULE 13G/A (Amendment No. 4)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) September 10, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (P]
RENN [Renren] SC 13G/A: SCHEDULE 13G/A (Amendment No. 4)* Renren Inc. (Name
[SCHEDULE 13G/A (Amendment No. 4)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) September 10, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (P]
NCTY [The9] F-1/A: (Original Filing)
[] [THE9 LIMITED CLASS A ORDINARY SHARES, PAR VALUE US$0.01 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [●], 2020 Maxim Group LLC As Representative of the several Underwriters named in Schedule I attached hereto Ladies and Gentlemen: Company Underwriters Agreement” Repr]
NCTY [The9] F-1/A:
[] [THE9 LIMITED CLASS A ORDINARY SHARES, PAR VALUE US$0.01 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [●], 2020 Maxim Group LLC As Representative of the several Underwriters named in Schedule I attached hereto Ladies and Gentlemen: Company Underwriters Agreement” Repr]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
